ProCE Banner Activity

In Vitro Susceptibility Testing Limitations in NTM Lung Disease

Clinical Thought
One of the most frustrating and misunderstood aspects of NTM disease management is the lack of clear correlation between in vitro activity of the drug and the outcome of in vivo treatment.

Released: December 01, 2021

Expiration: November 30, 2022

No longer available for credit.

Share

Faculty

David E. Griffith

David E. Griffith, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections
Department of Medicine
National Jewish Hospital
Denver, Colorado

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Insmed Incorporated

Partners

NTMIR

ProCE Banner

Faculty Disclosure

Primary Author

David E. Griffith, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections
Department of Medicine
National Jewish Hospital
Denver, Colorado

David E. Griffith, MD, has disclosed that he has received funds for research support from Insmed, Inc., consulting fees from AN2 Therapeutics and Insmed, Inc., and fees for non-CME/CE services from Insmed, Inc.